Role of Interleukins in Hepatitis B Virus Infection: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Konstantinos Dimitriadis
,
Stamatia Katelani
,
Maria Pappa
,
George E. Fragkoulis
,
Theodoros Androutsakos

Hepatitis B virus (HBV) infection is a worldwide medical issue with significant morbidity and mortality, as it is the main cause of chronic liver disease and hepatocellular carcinoma (HCC). Both innate and adaptive immune responses play a key role in HBV replication and suppression. The pathophysiological function of interleukins (IL) in the natural course of HBV has gained much attention as a result of the broad use of anti-interleukin agents for a variety of autoimmune diseases and the accompanying risk of HBV reactivation.

  • Hepatitis B virus
  • interleukins
  • chronic liver disease
  • immune response

1. Introduction

Hepatitis B virus (HBV) infection is a worldwide healthcare issue with significant morbidity and mortality, and it is the primary cause of chronic liver disease and hepatocellular carcinoma (HCC) [1][2]. According to the World Health Organization (WHO), in 2019, 296 million people worldwide were suffering from chronic HBV infection (CHB), with 1.5 million new infections each year, while the HBV burden was estimated at 116 million people in Western Pacific regions, 81 million people in Africa and 14 million people in Europe; in the same year, hepatitis B resulted in approximately 820,000 deaths [3].
HBV primarily affects hepatocytes and replicates within them. The virus enters the hepatocyte in 2 ways: via a low-affinity binding reaction between hepatitis B surface antigen (HBsAg) and the heparan sulfate proteoglycans (HSPG) on the cell surface and via a high-affinity binding reaction between the N-terminal part of the pre-S1 region of HBsAg and the hepatic bile acid transporter sodium taurocholate co-transporting polypeptide (NTCP), the main HBV hepatocyte receptor [4]. After entering the hepatocyte, relaxed circular DNA (rcDNA) is transported into the nucleus and converted into covalently closed circular DNA (cccDNA) [5]. In this way, HBV DNA remains in the hepatocyte, even after successful treatment with nucleos(t)ide analogues. In both chronic and acute infections, HBV induces liver injury mainly in a non-cytopathic way, mediated by the activation of the immune system.
Coordinated innate and adaptive immune responses are important for effective HBV clearance during acute infection. However, when the immune system fails to mount an effective response, viral persistence and consequent CHB occurs.
Interleukins (ILs), as fundamental elements of the immune system, regulate the outcome and characteristics of the adaptive immune response in a key manner. They play a crucial role in cellular communication by being generated and exerting their effects in a wide array of cell types; in this light, they form an intricate regulatory network. Up until now, 40 different ILs have been discovered, having 3 main functions, namely activating and regulating immune cells, transmitting information in a variety of cells, and participating in inflammatory response [6]. Regarding HBV infection, ILs seem to play an important role in viral persistence as well as in continuous liver damage (Table 1 and Figure 1), a role that has gained attention after the wide use of anti-IL agents for a variety of autoimmune diseases.
Figure 1. The complex interplay between different cytokines and hepatitis B virus. Black arrows indicate enhancement or secretion. Red arrows indicate suppression. Abbreviations: HBV: Hepatitis B virus, DC: dendritic cell, IL: Interleukin, NK: Natural killer, NKT: Natural killer T-cell, TLR2: Toll-like receptor 2, TNF: Tumor necrosis factor, IFN-γ: Interferon-gamma, TGF-b: Transforming growth factor beta, HbeAg: Hepatitis B envelope antigen, NTCP: Sodium taurocholate co-transporting polypeptide, NO: Nitric oxide, MHC: Major histocompatibility complex, Tregs: Regulatory T-cells, Th1-cells: T helper cells type 1, Th2-cells: T helper cells type 2, Th17-cells: T helper cells type 17, APCs: Antigen presenting cells, CTL: Cytotoxic T-cell.
Table 1. Interleukins presented in the text with their principal effects in immune response and their role in HBV infection.

Interleukins

Principal Effects

Contributions in HBV Infection

References

IL-1

Proinflammatory

Inhibition of HBV entry and replication

Th2-cell activation

[7][8][9][10][11]

IL-2

Promotion of effector T-cell differentiation

Maintenance of Tregs for suppressive functions

Regulation of HBV-specific T-cells

[12][13][14][15]

IL-4

Promotion of Th2-cell differentiation (humoral immunity)

Suppression of Th1-cell response

Cessation of HBV replication in specific HCC cell lines

[16][17]

IL-5

Maturation, differentiation and survival of B-cells

Probable negative association with HBV replication

[18][19]

IL-6

Stimulation of CD4+ T, B and Th17-cells

Inhibition of Tregs

Inhibition of HBV entry and replication

[20][21][22][23][24]

IL-10

Anti-inflammatory

Enhancement of HBV replication

Suppression of HBV-specific T-cell response

Mitigation of hepatic injury

[25][26][27][28][29][30][31][32][33][34][35][36][37]

IL-12

Proinflammatory

Enhancement of HBV-specific CD8+ T-cells in CHB

Downregulation of Tregs

[23][38][39][40][41][42]

IL-17

Proinflammatory

Ill-defined role in HBV infection

Probable association with CHB, cirrhosis and HCC

[23][43][44][45]

IL-21

Pleiotropic-Immunoregulatory

Boost of HBV-specific CD8+ T-cells and HBV suppression

[46][47][48][49][50][51][52][53]

IL-22

Promotion of cellular proliferation, resistance to apoptosis and tissue regeneration

Pro-inflammatory

Regulation of intrahepatic inflammation; tissue protection or liver injury progression depending on disease stage

[54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69]

IL-23

CD4+ T-cell proliferation

Enhancement of DC antigen presentation

Regulation of HBV-related hepatic inflammation

[23][70][71][72][73][74][75][76]

IL-35

Anti-inflammatoryImmunosuppression

Stimulation of HBV replication

Dampening of cytolytic and non-cytolytic activity of CTLs

[77][78][79][80][81][82][83][84][85][86][87][88][89][90]

Abbreviations: IL: Interleukin, HBV: Hepatitis B virus, Th2-cells: T helper cells type 2, Tregs: Regulatory T-cells, Th1-cells: T helper cells type 1, HCC: Hepatocellular carcinoma, Th17-cells: T helper cells type 17, CHB: chronic hepatitis B, DC: dendritic cell, CTLs: Cytotoxic T-cells.

2. Interleukin 1

Interleukin-1a (IL-1a) and interleukin-1b (IL-1b) belong to pro-inflammatory cytokines, with local and systemic roles, respectively [7]. When IL-1 binds to its receptor (IL-1R), it induces the production of other pro-inflammatory cytokines, like interleukin-6 (IL-6) [8].
IL-1 seems to inhibit HBV entry in the hepatocyte by down-regulating the expression of NTCP and blocking cccDNA transcription in 2 different ways: (a) through the inhibitory binding of nuclear factor-kB (NF-kB) to cccDNA and (b) through hepatocytes’ de-differentiation. The latter leads to loss of hepatocyte nuclear factor-4a (HNF4a), a transcription factor controlling HBV gene expression and replication, and thus to suppression of cccDNA transcription [8].

3. Interleukin-2

Interleukin-2 (IL-2) plays an important role in immune system regulation, as it is involved in T-cell differentiation and regulates immune response and homeostasis. IL-2 stimulation is crucial for the maintenance of T-regulatory (Treg) cells and the differentiation of CD4+ cells into effector T-cell subsets following antigen-mediated activation [91]. In CD8+ cells, IL-2 signals promote effector T-cell generation and differentiation into memory cells [12]. Interestingly, the use of IL-2 can amplify CD8+ T-cell responses, whereas the application of neutralizing IL-2 specific antibodies induces the expansion of the Treg cell population, thus favoring either immune stimulation or suppression [12][13][14][15][92].
Overall, IL-2 seems to be an interesting treatment option for HBV infection, mainly due to the enhancement of anti-viral CD8+ responses.

4. Interleukin-4

Interleukin-4 (IL-4) is a crucial anti-inflammatory cytokine secreted mainly by Th2 cells that leads to proliferation, differentiation and ultimately antibody production by mature B-cells. It shifts the adaptive immune response toward humoral immunity, as it promotes naïve CD4+ cells to differentiate into Th2 cells and inhibits interferon gamma (IFN-γ) production as well as T-helper 1 (Th1) responses [93].
Moreover, a handful of studies have demonstrated the capability of IL-4 to cease HBV replication in specific HCC cell lines [16][17].
As IL-4 boosts Th2 and inhibits Th1 immune responses, hence reducing liver inflammation, it could serve as a potential treatment option for HBV infection.

5. Interleukin-5

Interleukin-5 (IL-5) is a cytokine that augments humoral immune response through promotion of maturation, differentiation and survival of B-cells. It is primarily produced by Th2 cells, and secondarily by mast cells, eosinophils and natural killer T-cells (NKT) [18]. IL-5 plays a vital role in the immune system’s reaction against several infections [19][94][95], leading to leukocyte expansion and intensification of their activation status [96]. Recently published data show that IL-5 might play a pivotal role in HBV infection.
IL-5 seems to play an important role both in HBV suppression, as well as a predictive marker for treatment virological response; however, more data is required until safe consumptions are reached.

6. Interleukin-6

IL-6 is characterized by pleiotropic functions, involving not only immune response stimulation but also liver homeostasis and protein expression. IL-6 stimulates CD4+ T-cells, leading to antibody production by B-cells and enhancing the differentiation of naive T-cells to T-helper 17 (Th17) cells, while it also inhibits the differentiation of Tregs [20][21].
IL-6 also promotes liver regeneration and protects liver cells from injuries caused by immune responses, alcohol and viral infections [22][23][97].
As explained, IL-6 seems to play a critical role in HBV infection. In this line, physicians should be aware of the possibility of HBV reactivation when treating patients with autoimmune diseases and concurrent HBV infection with anti-IL-6 drugs [98].

7. Interleukin-10

Interleukin-10 (IL-10) plays a unique role in the anti-inflammatory regulation of the immune system. Its main cellular sources are monocytes/macrophages, as well as Th1, Th2, Th17 and Tregs. IL-10 is, to a lesser extent, produced by B-cells, dendritic cells (DC) and NKT cells [25][26][27][99]. IL-10 diminishes the secretion of pro-inflammatory cytokines and mediators and regulates the expression of cell surface molecules by myeloid cell subsets. In addition, it inhibits antigen presentation, thus acting as a potent anti-inflammatory cytokine, inducing immune tolerance and viral persistence [25][26][27][28][29][99].
As anticipated, IL-10 plays a pivotal role in HBV infection; in CHB patients, higher levels of IL-10 have been consistently noted [28][30][31]. Specifically, IL-10 enhances HBV replication and suppresses HBV-specific CD8+ T-cell immune responses, providing a defensive mechanism to mitigate immune-mediated hepatic injury that ultimately results in an increase in viral load and HBV infection persistence [30][31][32][33][34][35][36]. The importance of IL-10 in alleviating hepatic injury is shown in a study by Wang et al., where, in patients with HBV-ACLF, a decrease in IL-10 serum levels after HBV exacerbation was noted [37].
Overall, IL-10 seems to be pivotal in HBV replication and suppression of the anti-viral immune response; however, its anti-inflammatory role could be protective against the possibility of viral-related hepatotoxicity leading to liver failure.

8. Interleukin-12

IL-12, primarily produced by DC and phagocytes, serves as an immunomodulatory and pro-inflammatory cytokine [38][39][40]. IL-12 stimulates IFN-γ production, regulates the differentiation of Th1 cells, activates NK cells, and enhances their proliferation and cytotoxicity. Consequently, it acts as a crucial bridge connecting innate and adaptive immunity [38][39][40]. IL-12 secretion by DC subsets in response to various pathogens is dependent on different regulation of genes encoding IL-12, TLR expression, and cross-regulation between the different DC subsets, involving cytokines such as IL-10 and type I IFN [38]. Moreover, IL-12 down-regulates Tregs through the stimulation of nitric oxide production by antigen presenting cells (APCs), like macrophages [41][100]. Due to its close relation with lymphocyte activation, IL-12 is considered a potent anticancer agent with a significant role in T-cell-mediated cytolysis of cancer cells and malignant antigen presentation [101][102].
Due to its physiological actions, IL-12 has been used as an anti-viral drug for HBV. Cavanaugh et al. reported that treatment of HBV-infected mice with IL-12 interrupted HBV replication, probably through the induction of TNF-α and IFN α/β and γ [103]. Similarly, in patients with CHB, the use of IL-12 was correlated with significantly lower HBV DNA concentrations at the end of treatment, as well as during the 24 weeks of follow-up [104][105]. In a study by Rigopoulou et al., IL-12 was combined with lamivudine as a CHB treatment. Even though this combination regimen showed better anti-viral activity than lamivudine monotherapy, HBV DNA increased after lamivudine discontinuation [106]. Finally, Yang et al. suggested that increased serum IL-12 after 48 weeks of treatment with entecavir maleate contributed to an increased probability of HBeAg seroconversion [107].

9. Interleukin-17

The interleukin-17 (IL-17) family comprises six members (IL-17A to IL-17F) that mediate their biological functions by binding to receptors IL-17RA and IL-17RE, which form receptor complexes and initiate downstream signaling events in the IL-17 signaling pathway [108]. The most studied IL-17 family members are IL-17A and IL-17F. These interleukins promote their biological activities by binding to the heterodimeric receptor complex composed of IL-17RA and IL-17RC or by forming a ternary complex with IL-17RA and IL-17RC [43][108][109]. IL-17A induces several pro-inflammatory responses, mainly the production of TNF-α and β, IL-1β, IL-6 and other pro-inflammatory cytokines from Kupffer cells, DCs, hepatic stellate cells (HSC) and monocytes [23][43]. IL-17 seems to play a pivotal role in host defense against various fungal, bacterial and viral infections, including influenza, human immunodeficiency (HIV) and HCV viruses [110][111][112]. Moreover, IL-17 has an established role in many autoimmune diseases, especially ankylosing spondylitis, psoriasis and psoriatic arthritis; anti-IL-17 monoclonal antibodies are, in fact, broadly used in treatment of these diseases [113][114][115].
Altogether, the role of IL-17 in HBV infection is still uncertain, even though IL-17 has been associated with HBV-related liver injury.

10. Interleukin-21

Interleukin-21 (IL-21) is an immunoregulatory cytokine—secreted predominantly by follicular helper T (Tfh), Th17 and NKT cells [116][117]—that contributes to immune system regulation in a pleiotropic manner depending on its microenvironmental conditions [46]. IL-21 mainly controls maturation, activation and proliferation of CD4+, CD8+ T-cells and B cells, having a pivotal role in many autoimmune and inflammatory diseases [47][48][49].
Overall, IL-21 seems to play a critical role in host defense against HBV infection by enhancing both humoral and adaptive immune responses. Interestingly, a handful of studies have shown that IL-21 could also serve as a biomarker for HBeAg seroconversion.

11. Interleukin-22

Interleukin-22 (IL-22), a member of the IL-10 family, controls tissue responses to inflammation. IL-22 is mainly secreted by T-helper 22 (Th22), Th17 and Th1 cells, as well as γδT cells, cytotoxic T-cell subsets and NKT cells. IL-22 targets and regulates tissue cells to protect them from damage and to induce their regeneration [54][55][56].
As far as the role of IL-22 as a treatment option in CHB is concerned, Wang et al. showed that IL-22 producing CD3+ CD8-T-cells were suppressed after 48 weeks of treatment with peg-interferon [57]. In addition, Hao et al. found a notable decrease in IL-22 levels after 48 weeks of telbivudine treatment in a cohort of 24 CHB patients [118], suggesting that IL-22 could be used as a biomarker for disease response to treatment.
Collectively, the exact role of IL-22 in HBV infection is still unknown, since IL-22 seems to exhibit both pro- and anti-inflammatory effects, as already shown in other diseases [119].

12. Interleukin 23

Interleukin-23 (IL-23) is a heterodimeric cytokine belonging to the IL-12 cytokine family. The main biological functions of IL-23 consist of promoting CD4+ T-cell proliferation and inducing IFN-γ and IL-12 production, thus enhancing DC antigen presentation [23][70][71].
As opposed to other cytokines, like IL-22, the role of IL-23 in HBV infection seems to be quite straightforward; IL-23 production is enhanced by various HBV proteins and its overproduction leads to severe hepatic inflammation and consequent necrosis.

13. Interleukin 35

Interleukin-35 (IL-35) is a relatively new identified member of the IL-12 family, primarily secreted by Treg and regulatory B-cells (Breg) [120][121]. Its predominant action is immunosuppression, which is achieved through the inhibition of T-cell proliferation and effector functions [77][122]. IL-35 has a crucial role in immune-related diseases and in the maintenance of immunological tolerance [120][123][124][125][126]. Given the crucial role of Treg in blocking effective immune responses against HBV, IL-35 could be a very important contributor in CHB and even used as a therapeutic target [127]. Moreover, IL-35 seems to play a pivotal role in regulating the virus-specific Treg/Th17 balance [78]. The latter function constitutes this interleukin, an active contributor in the control of liver inflammation, by dampening antiviral immune responses and thus suppressing inflammatory responses [79][80][81].
Taken together, the above data support the multifaceted emerging effect of IL-35 on viral persistence and immune tolerance during HBV infection. Future investigation is essential for an in-depth understanding of IL-35′s immune regulation mechanisms, which may yield new immunotherapeutic strategies.

This entry is adapted from the peer-reviewed paper 10.3390/jpm13121675

References

  1. Schweitzer, A.; Horn, J.; Mikolajczyk, R.T.; Krause, G.; Ott, J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015, 386, 1546–1555.
  2. Brody, H. Hepatitis B. Nature 2022, 603, S45.
  3. The World Health Organization. Hepatitis B. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (accessed on 11 November 2023).
  4. Yuen, M.F.; Chen, D.S.; Dusheiko, G.M.; Janssen, H.L.A.; Lau, D.T.Y.; Locarnini, S.A.; Peters, M.G.; Lai, C.L. Hepatitis B virus infection. Nat. Rev. Dis. Primers 2018, 4, 18035.
  5. Schreiner, S.; Nassal, M. A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation-and Beyond? Viruses 2017, 9, 125.
  6. Akdis, M.; Burgler, S.; Crameri, R.; Eiwegger, T.; Fujita, H.; Gomez, E.; Klunker, S.; Meyer, N.; O’Mahony, L.; Palomares, O.; et al. Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases. J. Allergy Clin. Immunol. 2011, 127, 701–721.e70.
  7. Dinarello, C.A. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat. Rev. Rheumatol. 2019, 15, 612–632.
  8. Xia, Y.; Protzer, U. Control of Hepatitis B Virus by Cytokines. Viruses 2017, 9, 18.
  9. Ma, Z.; Liu, J.; Wu, W.; Zhang, E.; Zhang, X.; Li, Q.; Zelinskyy, G.; Buer, J.; Dittmer, U.; Kirschning, C.J.; et al. The IL-1R/TLR signaling pathway is essential for efficient CD8(+) T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model. Cell Mol. Immunol. 2017, 14, 997–1008.
  10. Li, Y.; Zhu, Y.; Feng, S.; Ishida, Y.; Chiu, T.P.; Saito, T.; Wang, S.; Ann, D.K.; Ou, J.J. Macrophages activated by hepatitis B virus have distinct metabolic profiles and suppress the virus via IL-1β to downregulate PPARα and FOXO3. Cell Rep. 2022, 38, 110284.
  11. Yang, C.Y.; Kuo, T.H.; Ting, L.P. Human hepatitis B viral e antigen interacts with cellular interleukin-1 receptor accessory protein and triggers interleukin-1 response. J. Biol. Chem. 2006, 281, 34525–34536.
  12. Boyman, O.; Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012, 12, 180–190.
  13. Gaffen, S.L.; Liu, K.D. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004, 28, 109–123.
  14. Malek, T.R. The biology of interleukin-2. Annu. Rev. Immunol. 2008, 26, 453–479.
  15. Zhong, S.; Zhang, T.; Tang, L.; Li, Y. Cytokines and Chemokines in HBV Infection. Front. Mol. Biosci. 2021, 8, 805625.
  16. Lin, S.J.; Shu, P.Y.; Chang, C.; Ng, A.K.; Hu, C.P. IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma cell line Hep3B. J. Immunol. 2003, 171, 4708–4716.
  17. Yao, Y.; Li, J.; Lu, Z.; Tong, A.; Wang, W.; Su, X.; Zhou, Y.; Mu, B.; Zhou, S.; Li, X.; et al. Proteomic analysis of the interleukin-4 (IL-4) response in hepatitis B virus-positive human hepatocelluar carcinoma cell line HepG2.2.15. Electrophoresis 2011, 32, 2004–2012.
  18. Takatsu, K. Interleukin-5 and IL-5 receptor in health and diseases. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2011, 87, 463–485.
  19. Vimali, J.; Yong, Y.K.; Murugesan, A.; Vishnupriya, K.; Ashwin, R.; Daniel, E.A.; Balakrishnan, P.; Raju, S.; Rosmawati, M.; Velu, V.; et al. Plasma interleukin-7 correlation with human immunodeficiency virus RNA and CD4+ T cell counts, and interleukin-5 with circulating hepatitis B virus DNA may have implications in viral control. Front. Med. 2022, 9, 1019230.
  20. Kimura, A.; Kishimoto, T. IL-6: Regulator of Treg/Th17 balance. Eur. J. Immunol. 2010, 40, 1830–1835.
  21. Lan, T.; Chang, L.; Wu, L.; Yuan, Y.F. IL-6 Plays a Crucial Role in HBV Infection. J. Clin. Transl. Hepatol. 2015, 3, 271–276.
  22. Kuo, T.M.; Hu, C.P.; Chen, Y.L.; Hong, M.H.; Jeng, K.S.; Liang, C.C.; Chen, M.L.; Chang, C. HBV replication is significantly reduced by IL-6. J. Biomed. Sci. 2009, 16, 41.
  23. Li, X.; Liu, X.; Tian, L.; Chen, Y. Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections. Clin. Rev. Allergy Immunol. 2016, 50, 41–54.
  24. Hösel, M.; Quasdorff, M.; Wiegmann, K.; Webb, D.; Zedler, U.; Broxtermann, M.; Tedjokusumo, R.; Esser, K.; Arzberger, S.; Kirschning, C.J.; et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009, 50, 1773–1782.
  25. Moore, K.W.; de Waal Malefyt, R.; Coffman, R.L.; O’Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19, 683–765.
  26. Mosser, D.M.; Zhang, X. Interleukin-10: New perspectives on an old cytokine. Immunol. Rev. 2008, 226, 205–218.
  27. Sabat, R.; Grütz, G.; Warszawska, K.; Kirsch, S.; Witte, E.; Wolk, K.; Geginat, J. Biology of interleukin-10. Cytokine Growth Factor. Rev. 2010, 21, 331–344.
  28. Brooks, D.G.; Trifilo, M.J.; Edelmann, K.H.; Teyton, L.; McGavern, D.B.; Oldstone, M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006, 12, 1301–1309.
  29. Bachmann, M.F.; Wolint, P.; Walton, S.; Schwarz, K.; Oxenius, A. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur. J. Immunol. 2007, 37, 1502–1512.
  30. Das, A.; Ellis, G.; Pallant, C.; Lopes, A.R.; Khanna, P.; Peppa, D.; Chen, A.; Blair, P.; Dusheiko, G.; Gill, U.; et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J. Immunol. 2012, 189, 3925–3935.
  31. Gong, Y.; Zhao, C.; Zhao, P.; Wang, M.; Zhou, G.; Han, F.; Cui, Y.; Qian, J.; Zhang, H.; Xiong, H.; et al. Role of IL-10-Producing Regulatory B Cells in Chronic Hepatitis B Virus Infection. Dig. Dis. Sci. 2015, 60, 1308–1314.
  32. Liu, Y.; Cheng, L.S.; Wu, S.D.; Wang, S.Q.; Li, L.; She, W.M.; Li, J.; Wang, J.Y.; Jiang, W. IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection. Clin Sci 2016, 130, 907–919.
  33. Huang, A.; Zhang, B.; Yan, W.; Wang, B.; Wei, H.; Zhang, F.; Wu, L.; Fan, K.; Guo, Y. Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1-induced IL-10. J. Immunol. 2014, 193, 5461–5469.
  34. Xu, L.; Yin, W.; Sun, R.; Wei, H.; Tian, Z. Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in hepatitis B virus-persistent mice. Hepatology 2014, 59, 443–452.
  35. Hyodo, N.; Nakamura, I.; Imawari, M. Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. Clin. Exp. Immunol. 2004, 135, 462–466.
  36. Hyodo, N.; Tajimi, M.; Ugajin, T.; Nakamura, I.; Imawari, M. Frequencies of interferon-gamma and interleukin-10 secreting cells in peripheral blood mononuclear cells and liver infiltrating lymphocytes in chronic hepatitis B virus infection. Hepatol. Res. 2003, 27, 109–116.
  37. Wang, K.; Wu, Z.B.; Ye, Y.N.; Liu, J.; Zhang, G.L.; Su, Y.J.; He, H.L.; Zheng, Y.B.; Gao, Z.L. Plasma Interleukin-10: A Likely Predictive Marker for Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Hepat. Mon. 2014, 14, e19370.
  38. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3, 133–146.
  39. Jia, Z.; Ragoonanan, D.; Mahadeo, K.M.; Gill, J.; Gorlick, R.; Shpal, E.; Li, S. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. Front. Immunol. 2022, 13, 952231.
  40. Xiong, S.Q.; Lin, B.L.; Gao, X.; Tang, H.; Wu, C.Y. IL-12 promotes HBV-specific central memory CD8+ T cell responses by PBMCs from chronic hepatitis B virus carriers. Int. Immunopharmacol. 2007, 7, 578–587.
  41. Brahmachari, S.; Pahan, K. Suppression of regulatory T cells by IL-12p40 homodimer via nitric oxide. J. Immunol. 2009, 183, 2045–2058.
  42. Schurich, A.; Pallett, L.J.; Lubowiecki, M.; Singh, H.D.; Gill, U.S.; Kennedy, P.T.; Nastouli, E.; Tanwar, S.; Rosenberg, W.; Maini, M.K. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog. 2013, 9, e1003208.
  43. Mills, K.H.G. IL-17 and IL-17-producing cells in protection versus pathology. Nat. Rev. Immunol. 2023, 23, 38–54.
  44. Huang, Z.; van Velkinburgh, J.C.; Ni, B.; Wu, Y. Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B. Liver Int. 2012, 32, 894–901.
  45. Arababadi, M.K.; Bidaki, M.Z.; Kennedy, D. IL-17A in hepatitis B infection: Friend or foe? Arch. Virol. 2014, 159, 1883–1888.
  46. Mehta, D.S.; Wurster, A.L.; Grusby, M.J. Biology of IL-21 and the IL-21 receptor. Immunol. Rev. 2004, 202, 84–95.
  47. Monteleone, G.; Pallone, F.; Macdonald, T.T. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor. Rev. 2009, 20, 185–191.
  48. Leonard, W.J.; Wan, C.K. IL-21 Signaling in Immunity. F1000Res 2016, 5.
  49. Mesas-Fernández, A.; Bodner, E.; Hilke, F.J.; Meier, K.; Ghoreschi, K.; Solimani, F. Interleukin-21 in autoimmune and inflammatory skin diseases. Eur. J. Immunol. 2023, 53, e2250075.
  50. Li, L.; Liu, M.; Cheng, L.W.; Gao, X.Y.; Fu, J.J.; Kong, G.; Feng, X.; Pan, X.C. HBcAg-specific IL-21-producing CD4+ T cells are associated with relative viral control in patients with chronic hepatitis B. Scand. J. Immunol. 2013, 78, 439–446.
  51. Li, J.; Ren, W.; Ma, W.; Zhang, J.; Shi, J.; Qin, C. Interleukin-21 responses in patients with chronic hepatitis B. J. Interferon Cytokine Res. 2015, 35, 134–142.
  52. Li, Y.; Tang, L.; Hou, J. Role of interleukin-21 in HBV infection: Friend or foe? Cell Mol. Immunol. 2015, 12, 303–308.
  53. Tang, L.; Chen, C.; Gao, X.; Zhang, W.; Yan, X.; Zhou, Y.; Guo, L.; Zheng, X.; Wang, W.; Yang, F.; et al. Interleukin 21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Chronic HBV Infection. J. Infect. Dis. 2019, 219, 750–759.
  54. Wolk, K.; Witte, E.; Witte, K.; Warszawska, K.; Sabat, R. Biology of interleukin-22. Semin. Immunopathol. 2010, 32, 17–31.
  55. Zenewicz, L.A.; Flavell, R.A. Recent advances in IL-22 biology. Int. Immunol. 2011, 23, 159–163.
  56. Zenewicz, L.A. IL-22 Binding Protein (IL-22BP) in the Regulation of IL-22 Biology. Front. Immunol. 2021, 12, 766586.
  57. Wang, L.Y.; Yang, X.Y.; Wu, Y.P.; Fan, Y.C. IL-22-producing CD3 + CD8- T cells increase in immune clearance stage of chronic HBV infection and correlate with the response of Peg-interferon treatment. Clin. Immunol. 2023, 250, 109320.
  58. Zhang, Y.; Cobleigh, M.A.; Lian, J.Q.; Huang, C.X.; Booth, C.J.; Bai, X.F.; Robek, M.D. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 2011, 141, 1897–1906.
  59. Zheng, W.P.; Zhang, B.Y.; Shen, Z.Y.; Yin, M.L.; Cao, Y.; Song, H.L. Biological effects of bone marrow mesenchymal stem cells on hepatitis B virus in vitro. Mol. Med. Rep. 2017, 15, 2551–2559.
  60. Zhao, J.; Zhang, Z.; Luan, Y.; Zou, Z.; Sun, Y.; Li, Y.; Jin, L.; Zhou, C.; Fu, J.; Gao, B.; et al. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology 2014, 59, 1331–1342.
  61. Feng, D.; Kong, X.; Weng, H.; Park, O.; Wang, H.; Dooley, S.; Gershwin, M.E.; Gao, B. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 2012, 143, 188–198.e187.
  62. Park, O.; Wang, H.; Weng, H.; Feigenbaum, L.; Li, H.; Yin, S.; Ki, S.H.; Yoo, S.H.; Dooley, S.; Wang, F.S.; et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 2011, 54, 252–261.
  63. Zhang, H.; Yan, X.; Yang, C.; Zhan, Q.; Fu, Y.; Luo, H.; Luo, H. Intrahepatic T helper 17 cells recruited by hepatitis B virus X antigen-activated hepatic stellate cells exacerbate the progression of chronic hepatitis B virus infection. J. Viral Hepat. 2020, 27, 1138–1149.
  64. Wei, X.; Wang, J.P.; Hao, C.Q.; Yang, X.F.; Wang, L.X.; Huang, C.X.; Bai, X.F.; Lian, J.Q.; Zhang, Y. Notch Signaling Contributes to Liver Inflammation by Regulation of Interleukin-22-Producing Cells in Hepatitis B Virus Infection. Front. Cell Infect. Microbiol. 2016, 6, 132.
  65. Zhang, J.; Liu, Z.; Liu, L.; Huang, M.; Huang, Y. Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3. Cytotechnology 2022, 74, 203–216.
  66. Shi, J.; Wang, Y.; Wang, F.; Zhu, Z.; Gao, Y.; Zhang, Q.; Du, Z. Interleukin 22 is related to development and poor prognosis of hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 2020, 44, 855–864.
  67. Schwarzkopf, K.; Rüschenbaum, S.; Barat, S.; Cai, C.; Mücke, M.M.; Fitting, D.; Weigert, A.; Brüne, B.; Zeuzem, S.; Welsch, C.; et al. IL-22 and IL-22-Binding Protein Are Associated With Development of and Mortality From Acute-on-Chronic Liver Failure. Hepatol. Commun. 2019, 3, 392–405.
  68. Cobleigh, M.A.; Robek, M.D. Protective and pathological properties of IL-22 in liver disease: Implications for viral hepatitis. Am. J. Pathol. 2013, 182, 21–28.
  69. Gao, Y.H.; Li, Q.Q.; Wang, C.G.; Sun, J.; Wang, X.M.; Li, Y.J.; He, X.T.; Xu, H.Q.; Niu, J.Q. The role of IL22 polymorphisms on liver cirrhosis in patients with hepatitis B virus: A case control study. Medicine 2019, 98, e17867.
  70. Duvallet, E.; Semerano, L.; Assier, E.; Falgarone, G.; Boissier, M.C. Interleukin-23: A key cytokine in inflammatory diseases. Ann. Med. 2011, 43, 503–511.
  71. Floss, D.M.; Moll, J.M.; Scheller, J. IL-12 and IL-23-Close Relatives with Structural Homologies but Distinct Immunological Functions. Cells 2020, 9, 2184.
  72. Wang, Q.; Zhou, J.; Zhang, B.; Tian, Z.; Tang, J.; Zheng, Y.; Huang, Z.; Tian, Y.; Jia, Z.; Tang, Y.; et al. Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis. PLoS Pathog. 2013, 9, e1003410.
  73. Xia, L.; Tian, D.; Huang, W.; Zhu, H.; Wang, J.; Zhang, Y.; Hu, H.; Nie, Y.; Fan, D.; Wu, K. Upregulation of IL-23 expression in patients with chronic hepatitis B is mediated by the HBx/ERK/NF-κB pathway. J. Immunol. 2012, 188, 753–764.
  74. Wang, Q.; Zheng, Y.; Huang, Z.; Tian, Y.; Zhou, J.; Mao, Q.; Wu, Y.; Ni, B. Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients. BMC Immunol. 2011, 12, 25.
  75. Bao, S.; Zheng, J.; Li, N.; Huang, C.; Chen, M.; Cheng, Q.; Li, Q.; Lu, Q.; Zhu, M.; Ling, Q.; et al. Role of interleukin-23 in monocyte-derived dendritic cells of HBV-related acute-on-chronic liver failure and its correlation with the severity of liver damage. Clin. Res. Hepatol. Gastroenterol. 2017, 41, 147–155.
  76. Khanam, A.; Trehanpati, N.; Sarin, S.K. Increased interleukin-23 receptor (IL-23R) expression is associated with disease severity in acute-on-chronic liver failure. Liver Int. 2019, 39, 1062–1070.
  77. Olson, B.M.; Sullivan, J.A.; Burlingham, W.J. Interleukin 35: A key mediator of suppression and the propagation of infectious tolerance. Front. Immunol. 2013, 4, 315.
  78. Yang, L.; Jia, S.; Shao, X.; Liu, S.; Zhang, Q.; Song, J.; Wang, W.; Jin, Z. Interleukin-35 modulates the balance between viral specific CD4(+)CD25(+)CD127(dim/-) regulatory T cells and T helper 17 cells in chronic hepatitis B virus infection. Virol. J. 2019, 16, 48.
  79. Shao, X.; Ma, J.; Jia, S.; Yang, L.; Wang, W.; Jin, Z. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection. Front. Cell Infect. Microbiol. 2017, 7, 472.
  80. Teng, D.K.; Liu, Y.; Lv, Y.F.; Wang, L.; Zhang, W.; Wang, J.P.; Li, Y. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection. Int. Immunopharmacol. 2019, 70, 252–259.
  81. Tang, Y.; Ma, T.; Jia, S.; Zhang, Q.; Liu, S.; Qi, L.; Yang, L. The Mechanism of Interleukin-35 in Chronic Hepatitis B. Semin. Liver Dis. 2021, 41, 516–524.
  82. Tao, N.N.; Gong, R.; Chen, X.; He, L.; Ren, F.; Yu, H.B.; Chen, J.; Ren, J.H. Interleukin-35 stimulates hepatitis B virus transcription and replication by targeting transcription factor HNF4α. J. Gen. Virol. 2018, 99, 645–654.
  83. Li, X.; Zhu, Q.; Ye, B.; Zhu, C.; Dong, Y.; Ni, Q. JNK/c-Jun pathway activation is essential for HBx-induced IL-35 elevation to promote persistent HBV infection. J. Clin. Lab. Anal. 2023, 37, e24860.
  84. Liu, F.; Tong, F.; He, Y.; Liu, H. Detectable expression of IL-35 in CD4+ T cells from peripheral blood of chronic hepatitis B patients. Clin. Immunol. 2011, 139, 1–5.
  85. Liu, Y.; Luo, Y.; Zhu, T.; Jiang, M.; Tian, Z.; Tang, G.; Liang, X. Regulatory B Cells Dysregulated T Cell Function in an IL-35-Dependent Way in Patients with Chronic Hepatitis B. Front. Immunol. 2021, 12, 653198.
  86. Yang, K.; Pan, Y.; Yan, B. Interleukin-35 induced by hepatitis B virus inhibits viral replication and viral antigen secretion in hepatocytes. Xi Bao Yu Fen. Zi Mian Yi Xue Za Zhi 2022, 38, 776–780.
  87. Zhou, Y.; Zhang, H.; Li, Y. IL-35 expression in peripheral blood CD4(+) T cells from chronic hepatitis B virus-infected patients directly correlates with virus load. Cytokine 2015, 73, 169–175.
  88. Li, X.; Liu, X.; Wang, W. IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases. Front. Cell Dev. Biol. 2021, 9, 614847.
  89. Li, X.; Tian, L.; Dong, Y.; Zhu, Q.; Wang, Y.; Han, W.; Liu, X.; Ni, Q.; Chen, Y.; Li, L. IL-35 inhibits HBV antigen-specific IFN-γ-producing CTLs in vitro. Clin Sci 2015, 129, 395–404.
  90. Dong, Y.; Li, X.; Yu, Y.; Lv, F.; Chen, Y. JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B. Life Sci. 2020, 252, 117663.
  91. Abbas, A.K.; Trotta, E.; Simeonov, D.; Marson, A.; Bluestone, J.A. Revisiting IL-2: Biology and therapeutic prospects. Sci. Immunol. 2018, 3, eaat1482.
  92. Hsieh, E.W.; Hernandez, J.D. Clean up by aisle 2: Roles for IL-2 receptors in host defense and tolerance. Curr. Opin. Immunol. 2021, 72, 298–308.
  93. Keegan, A.D.; Leonard, W.J.; Zhu, J. Recent advances in understanding the role of IL-4 signaling. Fac. Rev. 2021, 10, 71.
  94. Strestik, B.D.; Olbrich, A.R.M.; Hasenkrug, K.J.; Dittmer, U. The role of IL-5, IL-6 and IL-10 in primary and vaccine-primed immune responses to infection with Friend retrovirus (Murine leukaemia virus). J. Gen. Virol. 2001, 82, 1349–1354.
  95. Malla, N.; Fomda, B.A.; Thokar, M.A. Serum cytokine levels in human ascariasis and toxocariasis. Parasitol. Res. 2006, 98, 345–348.
  96. Broughton, S.E.; Dhagat, U.; Hercus, T.R.; Nero, T.L.; Grimbaldeston, M.A.; Bonder, C.S.; Lopez, A.F.; Parker, M.W. The GM-CSF/IL-3/IL-5 cytokine receptor family: From ligand recognition to initiation of signaling. Immunol. Rev. 2012, 250, 277–302.
  97. Giraldez, M.D.; Carneros, D.; Garbers, C.; Rose-John, S.; Bustos, M. New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology. Nat. Rev. Gastroenterol. Hepatol. 2021, 18, 787–803.
  98. Katelani, S.; Fragoulis, G.E.; Bakasis, A.D.; Pouliakis, A.; Nikiphorou, E.; Atzeni, F.; Androutsakos, T. HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: A systematic review and meta-analysis. Rheumatology 2023, 62, SI252–SI259.
  99. Saraiva, M.; Vieira, P.; O’Garra, A. Biology and therapeutic potential of interleukin-10. J. Exp. Med. 2020, 217, e20190418.
  100. Mirlekar, B.; Pylayeva-Gupta, Y. IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers 2021, 13, 167.
  101. Nguyen, H.M.; Guz-Montgomery, K.; Saha, D. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy. Cells 2020, 9, 400.
  102. van Herpen, C.M.; van der Voort, R.; van der Laak, J.A.; Klasen, I.S.; de Graaf, A.O.; van Kempen, L.C.; de Vries, I.J.; Boer, T.D.; Dolstra, H.; Torensma, R.; et al. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int. J. Cancer 2008, 123, 2354–2361.
  103. Cavanaugh, V.J.; Guidotti, L.G.; Chisari, F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 1997, 71, 3236–3243.
  104. Zeuzem, S.; Carreño, V. Interleukin-12 in the treatment of chronic hepatitis B and C. Antivir. Res. 2001, 52, 181–188.
  105. Carreño, V.; Zeuzem, S.; Hopf, U.; Marcellin, P.; Cooksley, W.G.; Fevery, J.; Diago, M.; Reddy, R.; Peters, M.; Rittweger, K.; et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J. Hepatol. 2000, 32, 317–324.
  106. Rigopoulou, E.I.; Suri, D.; Chokshi, S.; Mullerova, I.; Rice, S.; Tedder, R.S.; Williams, R.; Naoumov, N.V. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity. Hepatology 2005, 42, 1028–1036.
  107. Yang, J.; Guo, R.; Yan, D.; Lu, H.; Zhang, H.; Ye, P.; Jin, L.; Diao, H.; Li, L. Plasma Level of ADAMTS13 or IL-12 as an Indicator of HBeAg Seroconversion in Chronic Hepatitis B Patients Undergoing m-ETV Treatment. Front. Cell Infect. Microbiol. 2020, 10, 335.
  108. Li, X.; Bechara, R.; Zhao, J.; McGeachy, M.J.; Gaffen, S.L. IL-17 receptor-based signaling and implications for disease. Nat. Immunol. 2019, 20, 1594–1602.
  109. Goepfert, A.; Lehmann, S.; Wirth, E.; Rondeau, J.M. The human IL-17A/F heterodimer: A two-faced cytokine with unique receptor recognition properties. Sci. Rep. 2017, 7, 8906.
  110. Hamada, H.; Garcia-Hernandez Mde, L.; Reome, J.B.; Misra, S.K.; Strutt, T.M.; McKinstry, K.K.; Cooper, A.M.; Swain, S.L.; Dutton, R.W. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J. Immunol. 2009, 182, 3469–3481.
  111. Favre, D.; Mold, J.; Hunt, P.W.; Kanwar, B.; Loke, P.; Seu, L.; Barbour, J.D.; Lowe, M.M.; Jayawardene, A.; Aweeka, F.; et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2010, 2, 32ra36.
  112. Rowan, A.G.; Fletcher, J.M.; Ryan, E.J.; Moran, B.; Hegarty, J.E.; O’Farrelly, C.; Mills, K.H. Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J. Immunol. 2008, 181, 4485–4494.
  113. Batalla, A.; Coto, E.; González-Lara, L.; González-Fernández, D.; Gómez, J.; Aranguren, T.F.; Queiro, R.; Santos-Juanes, J.; López-Larrea, C.; Coto-Segura, P. Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort. J. Dermatol. Sci. 2015, 80, 111–115.
  114. Atzeni, F.; Carriero, A.; Boccassini, L.; D’Angelo, S. Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. Immunotargets Ther. 2021, 10, 141–153.
  115. Ogdie, A.; Coates, L.C.; Gladman, D.D. Treatment guidelines in psoriatic arthritis. Rheumatology 2020, 59, i37–i46.
  116. Tangye, S.G. Advances in IL-21 biology—Enhancing our understanding of human disease. Curr. Opin. Immunol. 2015, 34, 107–115.
  117. Asao, H. Interleukin-21 in Viral Infections. Int. J. Mol. Sci. 2021, 22, 9521.
  118. Hao, C.; Wang, J.; Kang, W.; Xie, Y.; Zhou, Y.; Ma, L.; Peng, M.; Bai, X.; Lian, J.; Jia, Z. Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B. Viral Immunol. 2013, 26, 336–342.
  119. Arshad, T.; Mansur, F.; Palek, R.; Manzoor, S.; Liska, V. A Double Edged Sword Role of Interleukin-22 in Wound Healing and Tissue Regeneration. Front. Immunol. 2020, 11, 2148.
  120. Xiang, X.G.; Xie, Q. IL-35: A potential therapeutic target for controlling hepatitis B virus infection. J. Dig. Dis. 2015, 16, 1–6.
  121. Choi, J.K.; Egwuagu, C.E. Interleukin 35 Regulatory B Cells. J. Mol. Biol. 2021, 433, 166607.
  122. Jiang, H.; Zhang, T.; Yan, M.X.; Wu, W. IL-35 inhibits CD8(+) T cells activity by suppressing expression of costimulatory molecule CD28 and Th1 cytokine production. Transl. Cancer Res. 2019, 8, 1319–1325.
  123. Shen, P.; Roch, T.; Lampropoulou, V.; O’Connor, R.A.; Stervbo, U.; Hilgenberg, E.; Ries, S.; Dang, V.D.; Jaimes, Y.; Daridon, C.; et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507, 366–370.
  124. Wang, R.X.; Yu, C.R.; Dambuza, I.M.; Mahdi, R.M.; Dolinska, M.B.; Sergeev, Y.V.; Wingfield, P.T.; Kim, S.H.; Egwuagu, C.E. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat. Med. 2014, 20, 633–641.
  125. Collison, L.W.; Chaturvedi, V.; Henderson, A.L.; Giacomin, P.R.; Guy, C.; Bankoti, J.; Finkelstein, D.; Forbes, K.; Workman, C.J.; Brown, S.A.; et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 2010, 11, 1093–1101.
  126. Yang, C.; Lei, L.; Pan, J.; Zhao, C.; Wen, J.; Qin, F.; Dong, F.; Wei, W. Altered CD4+ T cell and cytokine levels in peripheral blood and skin samples from systemic sclerosis patients and IL-35 in CD4+ T cell growth. Rheumatology 2022, 61, 794–805.
  127. Tavakolpour, S. Inhibition of regulatory cells as a possible cure of chronically hepatitis B virus infected patients. Immunol. Lett. 2016, 171, 70–71.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback